Table 1.

Clinical Features of All 16 Patients (previously Reported Patients and Our Patients) with Thrombotic Microangiopathies Accompanied with Polymyositis/dermatomyositis.

Patients		Age/ Sex		PM or DM		TTP or secondary TMA		From PM/ DM onset to TMA		Trigger		TMA with PM/DM exacerbation		Neurologic manifestation		Hemolytic anemia		Platelet count [/µl]		Renal disfunction		Reference
Treatment-effective group
1		57/F		PM		N/A		1 week		N/A		(+)		(+)		(+)		16,000		N/A		6
2		42/M		DM		N/A		6 months		N/A		(+)		(+)		(+)		20,000		N/A		7
3		50/F		DM		N/A		16 months		endothelial damage		(-)		(-)		(+)		41,000		(+)		8
4		70/F		PM		secondary TMA		6 years		N/A		N/A		(+)		(+)		32,000		(+)		9
5		69/F		DM		secondary TMA		5 years		N/A		(+)		(+)		(+)		35,000		(-)		Present case (Patient1)
6		75/M		DM		TTP		6 months		N/A		(+)		(+)		(+)		3,000		(+)		Present case (Patient2)
Treatment-ineffective group
7		65/F		DM		N/A		a few years		N/A		(+)		(+)		(+)		7,000		(+)		10
8		62/F		DM		N/A		a few months		N/A		(-)		(+)		N/A		<100,000		(+)		11
9		73/F		PM		N/A		a few years		Radiation treatment for cervical cancer		(-)		(+)		(+)		26,000		(+)		12
10		59/F		PM		N/A		a few weeks		N/A		(+)		(+)		(+)		16,000		(+)		13
11		60/M		DM		N/A		5 years		N/A		(+)		(+)		(+)		60,000		(+)		14
12		50/F		PM		N/A		8 months		N/A		(-)		(+)		(+)		96,000		(+)		15
13		53/F		PM		N/A		10 days		N/A		(+)		(-)		(+)		63,000		(+)		16
14		48/F		DM		N/A		1 year		pneumoniae, antibiotics		(-)		(+)		(+)		8,000		(+)		17
15		57/M		DM		N/A		13 months		N/A		(+)		(-)		(+)		<100,000		(+)		18
16		65/F		DM		secondary TMA		10 years		N/A		(+)		(-)		(+)		39,000		(+)		Present case (Patient3)

PM: polymyositis, DM: dermatomyositis, TMA: thrombotic microangiopathies, (+) positive, (-) negative, N/A: not available